Ivaniche 15 Tablet ER contains Ivabradine 15 mg as its active ingredient and is indicated for the treatment of chronic stable angina pectoris and chronic heart failure in patients with a normal sinus rhythm. Ivabradine acts by selectively inhibiting the If current in the sinoatrial node, resulting in heart rate reduction without affecting myocardial contractility or intracardiac conduction. This mechanism decreases myocardial oxygen demand, thereby alleviating angina symptoms and improving exercise tolerance. Ivaniche 15 Tablet ER is formulated as an extended-release tablet to provide a consistent plasma concentration, allowing for twice-daily dosing and enhanced patient compliance. It is particularly beneficial for patients who are intolerant to beta-blockers or require additional heart rate control despite beta-blocker therapy. The medication should be used under strict medical supervision, with regular monitoring of heart rate and rhythm to avoid bradycardia and other potential adverse effects. Contraindications include acute decompensated heart failure, severe hypotension, sick sinus syndrome, and concomitant use with strong CYP3A4 inhibitors. Common side effects may include visual disturbances, bradycardia, and dizziness. Ivaniche 15 Tablet ER offers a targeted approach to managing heart rate in cardiovascular conditions, improving quality of life and clinical outcomes when used appropriately.